Member Info for Bella6532

Ice...they don't issue the TR1 Avacta does. A new investor only have to tell Avacta officially when they hold 3% then at every 1 % increase. Some companies choose to quietly forget...or delay notification if they are filling a large order for themselves and then speak out once the order is completed.

As soon as Avacta receives details of holding from the investor they notify the market with a TR1...now, if there is still a news blackout these might be held off or if an investor is currently buying more they too might be holding off.

We need to know who the European guys are...

Pretty easy to work out...

'As a result of the Offer Price being less than 95 per cent. of the VWAP in the five-day trading period prior to the announcement of the Placing, the Direct Subscription and the REX Offer, the conversion price (118.75 pence) and the reset floor price (95 pence) will be recalculated by the calculation agent using an adjustment factor calculation as follows:

1. the adjustment factor will be (A+B)/(A+C), where:

1. A = number of Shares in issue immediately before the date of first public announcement of the terms (the "Pricing Date") of the Bookbuild;

2. B = aggregate gross proceeds of the Bookbuild divided by the Current Market Price ("CMP") on the Pricing Date of the Bookbuild, where CMP on the Pricing Date = arithmetic average of the five daily VWAPs immediately preceding the Pricing Date; and

3. C = number of Shares comprised in the Bookbuild.

The principal remaining under the Bonds was reduced by a further £2.55 million to £38.25 million on 22 January 2024 following the fifth quarterly amortisation.'

25-Mar-24 16:32:47 50.44375 200,000 Sell* 50.50 51.00 100.89k

and a lot of sells just above the 50 mark...

I haven't sat and dne the maths but I wonder if our Bond friends will be getting their price reduced to the 50 mark...if so, then I'd say we're seeing some naughty forward selling...or a friendly sale to a mate at mates rates...

Almostrich...have you seen this from June 2025:

https://avacta.com/2015-06-11/

This is called adjuvant treatment.

Sorry Timster...it's no joking matter...she's young and with 3 small kids. She has been recommended chemo because there's a high risk...

Geez..now Kate...bastxxx CANCER....

Timster..just saw it hun..the other half..went througgh esrlier today...that's why the price was dunked today..filling a nice little order or two...

'Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April.'

By the end of April...so C2 should start very early May...all being well the C3 in June and C4 July

Is that the aim..?

Rambo...yes I was throwing it into the mix intensionally to try and end the round and round and round...

As you say there's a big difference between Cohorts and Patients running in parallel.

The bottom line is they are aiming to be sble to speed up the whole process but as always they are totally reliant on other factors to keep it on track.

I think there's confusion here...sequentially = 1 then 2 the 3 then 4 etc...with dosage increasing as you move to the next cohort.

In the 2W the US starts with C1 @ 160

The UK starts with C2 @ 200

When US finishes C1 they start C3 @ 250

When the UK finishes C2 they start C4 @ 310

This is still classed as the same trial with the same perameters etc but they are running in parallel and the whole timeframe is speeded up...

This is how I see and how they will meet their timeframes.

For those who might not have joined the dots regarding Orphan Drug and Avactas decision to commercialise AVA6000 themselves...

'Designation of a drug as an orphan drug has yielded medical breakthroughs that might not otherwise have been achieved, due to the economics of drug research and development.[1] Examples of this can be that in the U.S. and the EU, it is easier to gain marketing approval for an orphan drug. There may be other financial incentives, such as an extended period of exclusivity, during which the producer has sole rights to market the drug. All are intended to encourage development of drugs which would otherwise lack sufficient profit motive to attract corporate research budgets and personnel.'

BV..it has to be the latter...overlaping is the only way to speed up the trial. It's what I was trying to explain yesterday...

As said it is one trial but overlaping (parallel) points woll in this case be accepted as AVA6000 is now deemed safe on all dose levels thru to x3.5 dox.

As I pointed earlier this morning. Even though 2W is deemed a safety trial still there is now more emphasis on improving the observed potential efficacy which in itself is huge. Can AVA6000 perform even better in a shorter time frame between lower doses.

If it does then P2 will (I assume) also be a 2W trial which again lead to a shorter trial timeframe...

This shortened time frame and PreCisions amazing (better than ever imagined so far) performance is why they needed to get financial ducks in a row now. The key being not only AVA6000 now being on a potentially much shorter timeframe to market but the pipeline workups...

The pipeline is where the deals will be done well before AVA6000 comes to market.

'Building on those positive findings, Avacta initiated a two-weekly dosing safety study in the United States, anticipating potential efficacy enhancements with the dosing schedule.'

LESS IS MORE...

BV..hence the fundraiser comment...

'progressing the current pre|CISIONTM and Affimer® pre-clinical pipelines.'

Your knowledge on the matter is amazing...scientific background?

Totally agree Icecool. PH comment is interesting. Having observed efficacy and what appears to be life extension the 2W isn't just about safety it's now also about efficacy...CC basically told us that in the link posted earlier. AVA6000 3W @ x3.5 dox = no serious side effects = SAFE with clearly observed efficacy.

AVA6000 2W @ potentially up to x3.5 = Safe too ? = even more and faster efficacy ?

BRING IT ON...

PH says...'It had recently commenced US testing of AVA6000 in new fortnightly dose escalation study (1.45x concentration) in order to see whether this shorter cycle time improves efficacy without impacting toxicity.'

Which sounds like the 2W trial is an efficacy trial..it's not...it's still a safety trial...isn't it???

And we may have forgotten they expected to see AVA6000 MTD after approx. 4 cohorts…still haven’t found it after 7…AMAZING!!!!! No wonder plans have changed…

‘Phase 1a • Objective: Assess safety and tolerability of AVA6000; determine MTD and/or recommended dose for further development • Approximately 4 Cohorts to achieve MTD • 15 to 20 patients • Patient Population: Locally advanced and/or metastatic pancreatic, colorectal, non-small cell lung, breast, head and neck (SCCHN), soft tissue sarcoma, ovarian and bladder cancer’

https://avacta.com/wp-content/uploads/2021/09/Avacta-Group-plc-Interim-Results-Final.pdf

BV...'Whereas brtezomib (Velcade) couldn't be used as is because it lacks that free, or any, amino group so a version that has that free amino group had to be designed (by Bachovchin's team).'

Hence AVA3996...

From June 2021 Results:

Example: Velcade • Bortezomib (Velcade, Takeda Pharmaceuticals) had annual sales of $1.2bn (2018) • BUT – approval limited to multiple myeloma because of dose limiting toxicities, • AND - coming off patent by 2022. • Pre-clinical development of AVA3996 pro-velcade will be restarted using placing proceeds. Example: Taxanes • Taxanes, such as the generic Paclitaxel, are used to treat a range of cancers such as prostate, breast and cervical. • Paclitaxel has global sales of $2.96bn (2018) and is expected to generate revenue of $6.63bn by end of 2025. • BUT - significant toxicities, such as myelosuppression and peripheral neuropathy, limit the effectiveness of paclitaxel-based treatment regimens.

Ideal for pre|CISIONTM tumour activation to create safer and proprietary pro-drugs. Conservatively assume the pre|CISIONTM prodrug versions of these can achieve similar market sizes delivering 5-10% royalty to Avacta plus development milestones. Potential for a pipeline of pre|CISION pro-drugs, some of which have already been synthesized, with an addressable market of many $bn pa. Including but not limited to: • preCISION Velcade • preCISION Paclitaxel • preCISION Oxaliplatin • preCISION Gemcitabine • preCISION Capecitabine • preCISION PARP inhibitor • preCISION PD-1 Inhibitor • preCISION AKT inhibitor • preCISION Balixafortide

https://avacta.com/wp-content/uploads/2021/09/Avacta-Group-plc-Interim-Results-Final.pdf